VANCOUVER, British Columbia and TORONTO, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and ImmunoBiochem Corporation, today announced entering into a Collaboration and Option agreement to develop superior antibody-drug conjugates.  The companies will evaluate the prospect of combining ImmunoBiochem’s proprietary antibody and APC’s site-selective conjugation technology to produce ADCs with superior properties, targeting triple-negative breast cancer.  

ImmunoBiochem, one of the winners of the Innovation Challenge at the 2018 RESI in San Francisco, is commercializing ADCs targeted against unique antigens in the secretome of cancer cells.  Upon successful evaluation, ImmunoBiochem has been granted the rights to license APC’s proprietary site-selective conjugation technology to further develop its antibody drug conjugate candidate towards the clinic.  The pre-negotiated licensing terms include upfront and milestone payments and royalties.   

“Evaluating APC’s technology to site-selectively modify our novel conjugates may help us create better drug candidates and generate a profound impact in the treatment of triple-negative breast cancer,” said Anton Neschadim, CEO of ImmunoBiochem Corporation.

“We are pleased to collaborate with ImmunoBiochem on this project, as this could result in developing premier cancer treatments for this challenging indication,” commented Randal Chase, CEO of Advanced Proteome Therapeutics.

APC´s technology enables the coupling of a cytotoxic payload site-selectively to an antibody of interest without the need for genetically engineering or enzymatically modifying it. This may yield more homogeneous products with certain additional advantages such as an increase in stability in the circulation, fewer side effects and facilitating further pre-clinical and clinical drug development.

About Advanced Proteome Therapeutics

Advanced Proteome Therapeutics Corporation (APC) is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity, and lower toxicity than other therapies that can also attack healthy cells.  Advanced Proteome is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential.   www.advancedproteome.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Advanced Proteome Therapeutics Corporation
Dr. Randal D. Chase
President and Chief Executive Officer
Tel: 905-252-3629
http://www.advancedproteome.com

About ImmunoBiochem Corporation

ImmunoBiochem is a privately held biopharmaceutical company that has developed a disruptive approach to targeting unique proteins in the secretomes of cancer cells with Antibody Drug Conjugates (ADCs) - an emerging class of anticancer therapeutics that combine the selectivity of targeted biologics with the potency of highly cytotoxic small-molecule drugs. ImmunoBiochem has identified a class of molecular targets that are secreted by cancer cells, but not healthy cells, and accumulate in the tumor microenvironment. These cancer targets possess unique properties enabling the highly-selective delivery of toxic payloads to cancer cells with engineered ADC therapeutics, while leaving normal cells unharmed. ImmunoBiochem’s next-generation ADCs for oncology aim to offer a superior safety profile and broad therapeutic window, preventing on-target toxicities against normal, healthy cells that are common with many ADCs. Its lead candidates are being developed for Triple-Negative Breast Cancer (TNBC) – an aggressive disease for which no targeted biological therapeutic treatment options are currently available.

FOR FURTHER INFORMATION PLEASE CONTACT:

ImmunoBiochem Corporation
Anton Neschadim, CEO
JLABS @ Toronto, MaRS Discovery District
661 University Avenue, Suite 1300, 13102H
Toronto, ON, M5G 0B7, Canada
Tel: +1 (416) 897-2789
Email: ceo@immunobiochem.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will”, "should”, "future", "potential" or similar expressions or by a general discussion of the Company’s strategies, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.